Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Adding serial N-terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Performance of Prognostic Risk Scores in Heart Failure Patients: Do Sex Differences Exist?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Socioeconomic position and one-year mortality risk among patients with heart failure: A nationwide register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A prospective three-year follow-up study on the clinical significance of anti-neuronal antibodies in acute psychiatric disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
AIMS: This study was designed to evaluate a new NT-proBNP monitoring concept in outpatients with systolic heart failure (HF). METHODS AND RESULTS: This was a multicentre, prospective randomized open-label blinded endpoint study. A total of 407 systolic HF patients were allocated to either clinical management (n = 208) or clinical management + NT-proBNP monitoring (n = 199) and followed for 2.5 years. If NT-proBNP increased >30%, a clinical checklist was completed and treatment initiated. The patients were matched at randomization and were 73 years old, 25% were females, 85% were NYHA class I-II, LVEF was 30%, and NT-proBNP 1955 pg/mL. NT-proBNP monitoring did not improve outcome, the hazard ratio for the primary composite endpoint (death or a cardiovascular admission) being 0.96 [95% confidence interval (CI) 0.71-1.29, P = 0.766]. NT-proBNP monitoring did not induce a significant change in the pharmacological strategy (P > 0.05 for all comparisons). In patients in whom NT-proBNP increased >30% (25% of the patients) during follow-up, a higher frequency of admission (69% vs. 47%, P = 0.002), a higher number of admission days (14 vs. 5 days, P = 0.003) and number of admissions (2 vs. 1, P = 0.009), and a lower quality of life (P = 0.032) and a poorer functional class (37% vs. 18% in NYHA class III-IV, P <0.001) were observed. CONCLUSIONS: Adding serial measurements of NT-proBNP to optimal clinical management was not associated with a change in pharmacological strategy and did not improve outcome. However, survivors in whom NT-proBNP increased >30% showed a poorer functional class, clinical outcome, and quality of life.Trial registrationwww.centerwatch: 173491 (NorthStar).
Original languageEnglish
JournalEuropean Journal of Heart Failure
Pages (from-to)818-827
Number of pages9
ISSN1388-9842
DOIs
Publication statusPublished - Jul 2013

ID: 38681679